期刊文献+

盐酸椒苯酮胺冻干制剂辅料筛选 被引量:1

Optimization of the adjuvant of piperphentonamine hydrochloride freeze-dried preparation
暂未订购
导出
摘要 目的考察适合盐酸椒苯酮胺冻干制剂的辅料。方法配制含不同质量分数辅料的盐酸椒苯酮胺溶液(2 mg/mL,5 mL/支),包括甘露醇、蔗糖、乳糖、甘氨酸、右旋糖酐,经冻干后观察制剂的外观、含量、澄清度、颜色、pH等特性,以筛选盐酸椒苯酮胺冻干制剂的辅料。结果冻干制剂复溶后,甘露醇组出现乳浊;3%~5%蔗糖组色偏深;甘氨酸组乳浊并色偏深;乳糖和右旋糖酐组的外观、含量、澄清度、颜色均较佳。结论优选乳糖作为盐酸椒苯酮胺冻干制剂的辅料。 Objective To investigate the adjuvant of piperphentonamine hydrochloride freeze-dried preparation. Methods The different adjuvants including mannitol, cane sugar, lactose, glycine and dextran were optimized by dispensing piperphentonamine hydrochloride liquids with apperanee, content, clarity, color and pH. Results The mannitol groups show opacifying. 3% -5% cane sugar groups show deep color. The glycine groups show opacifying and deep color. The lactose and dextran groups show qualified shape, content, clarity and color. Conclusions Lactose is a qualified adjuvant of piperphentonamine hydroehloride freeze-dried preparation.
出处 《广东药学院学报》 CAS 2012年第1期13-16,共4页 Academic Journal of Guangdong College of Pharmacy
基金 国家"十二五"重大新药创制科技重大专项(2011ZX091011-003) 科技部创新基金(10C26214412687) 广东省中国科学院全面战略合作项目(2009B091300065) 广州市专利技术产业化示范项目(200903) 广州市重大专项课题(2008A1-E4161)
关键词 盐酸椒苯酮胺 甘露醇 乳糖 冻干制剂 piperphentonamine hydroehloride mannitol lactose freeze-dried preparation
  • 相关文献

参考文献3

二级参考文献42

  • 1牟英,孟志云,窦桂芳.椒苯酮胺在比格犬体内的药代动力学研究[J].中国血液流变学杂志,2006,16(3):338-340. 被引量:12
  • 2Parissis JT, Andreadou I, Bistola V, et al. Novel biologic mechanisms of levosimendan and its effect on the failing heart[J]. Expert Opin Invest Drags, 2008, 17(8) :1143 -1150.
  • 3Antoniades C, Tousoulis D, Koumallos N, et al. Levosimendan: beyond its simple inotropic effect in heart failure[J]. Pharmacol Ther. 2007, 114(2) :184 - 197.
  • 4Pinto BB, Rehberg S, Ertmer C, et al. Role of levosimendan in sepsis and septic shock [ J ]. Curr Opin Anaesthesiol, 2008, 21 (2) :168 - 177.
  • 5Lehtonen L, Poder P. The utility of levosimendan in the treatment of heart failure[J]. Ann Med, 2007, 39( 1 ) :2 - 17.
  • 6Archan S, Toiler W, Levosimendan: current status and future prospects[ J ]. Curr Opin Anaesthesiol, 2008, 21 ( 1 ) :78 - 84.
  • 7Kota B, Prasad AS, Economides C, et al. Levosimendan and calcium sensitization of the contractile proteins in cardiac muscle : impact on heart failure[J]. J Cardiovasc Pharmacol Ther, 2008, 13(4) :269 -278.
  • 8Silva-Cardoso J, Ferreira J, Oliveira-Soares A, et al. Effectiveness and safety of levosimendan in clinical practice[J]. Rev Port Cardiol, 2009, 28 (2) : 143 - 154.
  • 9Duygu H, Nalbantgil S, Zoghi M, et al. Comparison of ischemic side effects of levosimendan and dobutamine with integrated backscatter analysis[J]. Clin Cardiol, 2009, 32(4) : 187 - 192.
  • 10Yilmaz MB, Yontar C, Erdem A, et al. Comparative effects of levosimendan and dobutamine on right ventricular function in patients with biventricular heart failure [ J ]. Heart Vessels, 2009, 24(1) :16 -21.

共引文献27

同被引文献6

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部